Metformin Hydrochloride Extended-Release Tablets, USP 750 mg, 100 count HDPE bottles NDC# 72578-...

FDA Drug Recall #D-0392-2022 - Class II, December 27, 2021

Recall Summary

Recall Number D-0392-2022
Classification Class II - Moderate risk
Date Initiated December 27, 2021
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm VIONA PHARMACEUTICALS INC
Location Cranford, NJ
Product Type Drugs
Quantity 23,8416/100 count bottles

Product Description

Metformin Hydrochloride Extended-Release Tablets, USP 750 mg, 100 count HDPE bottles NDC# 72578-036-01

Reason for Recall

CGMP Deviations- Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.

Distribution Pattern

Product was distributed to 17 wholesalers who further distributed the product to 85 locations.

Lot / Code Information

M008130 06/2022, M008131 06/2022, M008132 06/2022, M008133 06/2022, M010080 07/2022, M010081 07/2022, M011029 08/2022, M011030 08/2022, M011031 08/2022, M011032 08/2022, M011304 08/2022, M013394 09/2022, M013395 09/2022, M013396 09/2022, M013966 09/2022, M013967 09/2022, M100831 12/2022, M100832 12/2022, M100833 01/2023, M100834 01/2023, M101267 01/2023, M102718 01/2023, M102719 01/2023

Other Recalls from VIONA PHARMACEUTICALS INC

Recall # Classification Product Date
D-0016-2026 Class II Tavaborole Topical solution 5%, 10 mL bottle, R... Oct 6, 2025
D-0595-2025 Class II Tavaborole Topical Solution 5%, 10 mL per glass... Aug 12, 2025
D-0172-2025 Class II Dapsone Gel 7.5%, 90 g, Rx Only, Manufactured b... Dec 10, 2024
D-0171-2025 Class II Dapsone Gel 7.5%, 60 g, Rx Only, Manufactured b... Dec 10, 2024
D-0038-2025 Class II Dapsone Gel 7.5%, 60 gram pump, Rx Only, Manufa... Oct 29, 2024

Frequently Asked Questions

cGMP stands for Current Good Manufacturing Practice, the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful, in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications, even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications, use a drug take-back program.